Garde Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Garde Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15	Closed	-$1.24K	–	823
2025 Q2	$1.24K	Hold	15	–	–	﹤0.01%	663
2025 Q1	$1.22K	Buy	+15	New	+$1.34K	﹤0.01%	649

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Garde Capital's XBI Position: Q3 2025 in Review

Garde Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2025, closing a stake of 15 shares — an estimated $1.24K sold.

Garde Capital first reported a position in XBI in Q1 2025 and held it in 2 quarters. The position peaked at $1.24K in Q2 2025. 656 funds tracked by Wall St. Rank hold XBI as of Q3 2025.

Garde Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 15 State Street SPDR S&P Biotech ETF shares in Q3 2025, an estimated $1.24K.
Garde Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2025 and held it in 2 quarters.
Garde Capital's State Street SPDR S&P Biotech ETF position peaked at $1.24K in Q2 2025.
656 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.